Skip to main content

The End of Big Pharma

  • 96 Accesses

Abstract

Not only are the costs of medicines high, which is why prescription medicines alone account for the third largest cost factor in the healthcare system, but the costs and risks for the pharmaceutical industry have also exploded. At the same time, the industry seems to be running out of ideas, which I see as one of the key symptoms of the crisis in medicine. This is where the concept of defining symptoms as disease and the treatment of symptoms as therapy was the first to suffer shipwreck. At least at the level of drug approval or negotiations with health insurance companies, every new drug is compared with existing drugs for every indication. If no real advantage is apparent, then such new developments fail or at least do not generate the sales revenues they would have to generate to recoup the previous costs and the costs of all failed projects of the same company.

This is a preview of subscription content, access via your institution.

Buying options

eBook
USD   19.99
Price excludes VAT (USA)
  • ISBN: 978-3-030-95293-8
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   29.99
Price excludes VAT (USA)
Fig. 7.1
Fig. 7.2
Fig. 7.3
Fig. 7.4

Notes

  1. 1.

    Wouters OJ et al. (2020) Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323:844–853, https://doi.org/10.1001/jama.2020.1166

  2. 2.

    Huseyin N et al. (2019) Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014–16: cross sectional analysis. BMJ 366:l5221, https://www.bmj.com/content/366/bmj.l5221

  3. 3.

    Ringel MS et al. (2020) Breaking Eroom’s Law. Nat Rev Drug Discov. 19:833–834, https://doi.org/10.1038/d41573-020-00059-3. PMID: 32300238.

  4. 4.

    Stott K (2017) Pharma’s broken business model: An industry on the brink of terminal decline. EndpointNews; https://endpts.com/pharmas-broken-business-model-an-industry-on-the-brink-of-terminal-decline/; Stott K (2018) Pharma’s broken business model - Part 2: Scraping the barrel in drug discovery. EndpointNews; https://endpts.com/pharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery/

  5. 5.

    Flintrop J (2003) The “disease inventors”: the honest doctor is the stupid one. Dtsch Arztebl 100:A-3352/B-2791/C-2611; https://www.aerzteblatt.de/archiv/39864/Die-Krankheitserfinder-Der-ehrliche-Arzt-ist-der-Dumme; Blech J (2005) Die Krankheitserfinder: Wie wir zu Patienten gemacht werden, Fischer.

  6. 6.

    Jefferson T et al. (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews:CD008965, https://10.1002/14651858.CD008965.pub4

  7. 7.

    Wilson D (2011) Merck to Pay $950 Million Over Vioxx. New York Times, https://www.nytimes.com/2011/11/23/business/merck-agrees-to-pay-950-million-in-vioxx-case.html

  8. 8.

    Krumholz H et al. (2007) What have we learnt from Vioxx? BMJ 334:120, https://doi.org/10.1136/bmj.39024.487720.68

  9. 9.

    Harris G (2009) Pfizer Pays $2.3 Billion to Settle Marketing Case. New York Times, https://www.nytimes.com/2009/09/03/business/03health.html?_r=0&auth=redirect-apple

  10. 10.

    Serafino P & Kitamura M (2011) Glaxo to Pay $3 Billion to Settle U.S. Sales, Avandia Cases. Bloomberg, https://www.bloomberg.com/news/articles/2011-11-03/glaxo-agrees-to-pay-3-billion-to-settle-u-s-probe-into-sales-marketing

  11. 11.

    Curfman GD (1997) Diet Pills Redux. N Engl J Med 337:629–630, http://www.nejm.org/doi/full/10.1056/NEJM199708283370909; Mark EJ et al. (1997) Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 337:602–606.

  12. 12.

    Tansey B (2004) Huge penalty in drug fraud/Pfizer settles felony case in Neurontin off-label promotion. SFGATE, https://www.sfgate.com/business/article/Huge-penalty-in-drug-fraud-Pfizer-settles-2759293.php; Reuters Editorial (2010) US jury’s Neurontin ruling to cost Pfizer $141 mln. Reuters, https://de.reuters.com/article/pfizer-neurontin/us-jurys-neurontin-ruling-to-cost-pfizer-141-mln-idUSN259778920100325

  13. 13.

    Editor (2018) Telithromycin: a welcome market withdrawal. Prescrire Int 27:210, https://english.prescrire.org/en/81/168/55234/0/NewsDetails.aspx; Ross DB (2007) The FDA and the Case of Ketek. N Engl J Med 356:1601–1604, https://doi.org/10.1056/NEJMp078032

  14. 14.

    Tong A (2021) In a rare legal defeat, Bristol Myers Squibb and Sanofi fined $834M for ‘deceptive marketing’ on best-selling blood thinner Plavix. Endpoint News, https://endpts.com/in-a-rare-legal-defeat-bristol-myers-squibb-and-sanofi-fined-834m-for-deceptive-marketing-on-best-selling-blood-thinner-plavix/

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Schmidt, H.H.H.W. (2022). The End of Big Pharma. In: The end of medicine as we know it - and why your health has a future. Springer, Cham. https://doi.org/10.1007/978-3-030-95293-8_7

Download citation